Company Overview:
Incorporated in 1981, Emcure Pharmaceuticals Ltd manufactures and markets pharmaceutical products globally, serving diverse therapeutic segments. Presenting below its Q1 FY26 Earnings Results.
Financial Highlights for Q1 FY26:
- Revenue: ₹2,101 crore, up 15.76% year-on-year from ₹1,815 crore
- Total Expenses: ₹1,810 crore, up 10.91% year-on-year from ₹1,632 crore
- Consolidated Net Profit: ₹215 crore, up 40.52% year-on-year from ₹153 crore
- Earnings Per Share (EPS): ₹10.92, up 37.36% year-on-year from ₹7.95
Performance Insights:
- Revenue growth of nearly 16% was supported by increased product sales across domestic and international markets.
- Expenses rose at a slower pace than revenues, driving margin expansion and enhanced profitability.
- Net profit surged over 40%, reflecting operational efficiencies and favorable product mix.
- Emcure continues to focus on strengthening its global footprint and expanding its pharmaceutical portfolio.
Outlook:
The company aims to sustain growth through innovation, market expansion, and cost management strategies in FY26 and onwards.
Explore the company’s past earnings and latest concall transcripts, click here to visit the AlphaStreet India News Channel.
Most Popular
Cochin Shipyard Ltd (COCHINSHIP) Q4 FY22 Earnings Concall Transcript
Cochin Shipyard Limited (NSE:COCHINSHIP) Q4 FY22 Earnings Concall dated May. 26, 2022 Corporate Participants: Madhu S Nair -- Chairman & Managing Director Jose V J -- Director Finance Analysts: Vastupal Shah
All you need to know about Antony Waste Handling Cell in one article
Can you guess the name of the company that was listed during the IPO frenzy in 2020 and is the second largest player in the Indian municipal waste management industry?
Demystifying the Leading Non-Ferrous Recycling Company of India
“Hey, how is the market doing today?” “Oh!, its falling tremendously since morning” I am sure news like these might be a common topic of discussion for you nowadays. Interestingly,